The report can also be downloaded from:
http://www.carrerasresearch.org

Photography
Photographic archives of the Josep Carreras Leukaemia Foundation and the Josep Carreras Leukaemia Research Institute
“The Institute's three campuses are surrounded by excellent scientific and health service facilities. It is the aim of our project to enhance, integrate, share and strengthen this already excellent situation even more, and this is already being done at the management level, by simplifying and sharing structures, and at the scientific level, by integrating cross-section and multi-site services to avoid unnecessary duplication. Everything we do is focused on making leukaemia and other malignant blood diseases 100% curable one day.”

Josep Carreras
President of the Board of Trustees
Josep Carreras Leukaemia Research Institute (IJC)
About us
Welcome
Who we are
What we research
Mission, vision and values
Schematic model

Scientific activities
Research groups
Research projects
Technology platforms
Clinical trials
Innovation and transferability

Scientific production
Publications
Impact factors

Training activities
Graduate and post-graduate
Theses read
Seminars and sessions
Courses and congresses

Our team
Governing bodies
Organisational chart
Human resources

Financial data
Income statement
Balance sheet
Fundraising

Cooperation
Agreements
Institutions involved

Communication
Scientific dissemination

Upcoming challenges
New building
SUMA agreement
Once again the IJC's annual report is testimony to the excellent research being carried out at the three Josep Carreras campuses. Our congratulations are due, therefore, to everyone for their magnificent work and scientific rigour.

2015 was a year in which progress was made in the fight against leukaemia. It was a year of combined scientific efforts, continuing cooperation and commitment to society.

And our centre is seeing how its facilities are expanding with the new building in Badalona, made possible by funding from the Josep Carreras Foundation.

Highlights of the IJC's leadership are the construction of the new building in Badalona and the agreements about the SUMA project between the Germans Trias Institute (IGTP) and the Institute for Predictive and Personalised Cancer Medicine (IMPPC).

With all this in mind, it is our pleasure to invite you to learn more from the following pages about the activities in 2015, activities which have earned this centre a leading position in biomedical research to confront leukaemia.

Evarist Feliu
President of the Delegate Committee
Josep Carreras Leukaemia Research Institute (IJC)
Who we are

Three campuses united to win the battle against leukaemia and other malignant blood diseases

The Josep Carreras Leukaemia Research Institute (IJC), a Generalitat de Catalunya Research Centre (CERCA), was established with the aim of promoting biomedical research into, and the development of, personalised medicine in the field of malignant blood diseases, especially leukaemia. It is a centre without precedent which, with the work and dedication of researchers from around the world, uses the most innovative technologies to try to vanquish leukaemia and other malignant blood diseases.

The IJC has three independent and coordinated scientific campuses: the Hospital Clínic-UB Campus, located at the research facilities of Barcelona’s Hospital Clínic, and those of the University of Barcelona (UB) Faculty of Medicine, coordinated by Dr. Álvaro Urbano Ispizua, under the research direction of Dr. Pablo Menéndez; the Catalan Institute of Oncology/Germans Trias i Pujol Campus in Badalona, located near the Germans Trias i Pujol University Hospital and its research foundation and the Autonomous University of Barcelona (UAB) Germans Trias i Pujol Teaching Unit. The ICO-Germans Trias i Pujol Campus is coordinated by Dr. Evarist Feliu and the Research Director is Dr. Francesc Solé. The third campus is the Sant Pau Campus and its research foundation, located within the health care facilities of the Hospital de la Santa Creu i Sant Pau and the UAB’s Sant Pau teaching unit, coordinated by Dr. Jordi Sierra. The IJC’s Hospital Clínic-UB Campus reaffirms the UB Faculty of Medicine and the Hospital Clínic's scientific commitment to excellence in the field of hematology, which commenced with the work of Prof. Farreras Valentí and which has been able to continue thanks to the extraordinary work carried out by Prof. Ciril Rozman and those who studied under him.
What we research

The opportunities offered by research into leukaemia and other malignant blood diseases are evident. The strategies for responding to these opportunities have to employ the methodologies and technologies that correspond to the challenges presented by the quest to find a cure for these diseases. Consequently, the lines of research that the Josep Carreras Leukaemia Research Institute has established are as follows:

01 Acute leukaemias

02 Chronic lymphoproliferative syndromes

03 Chronic myeloproliferative neoplasms

04 Monoclonal gammopathies

05 Myelodysplastic syndromes

06 Malignant blood diseases and coagulation

07 Associated complications and therapeutic procedures

08 Transplantation of hematopoietic progenitors and cell therapy

09 Epidemiological research

010 Clinical research
Mission

The Josep Carreras Leukaemia Research Institute's mission is to carry out research into the basic, epidemiological, preventive, clinical and transferable aspects of leukaemia and other malignant blood diseases in order to find a cure for them.

Vision

The Josep Carreras Leukaemia Research Institute's vision is to be a world-renowned, multi-campus research centre of excellence that contributes towards improved outcomes and a cure for leukaemia and other malignant blood diseases through innovation, sustainability, social responsibility, talent and professional expertise.

Values

Altruism and example-setting.
Patient-orientated, proximity.
Staff commitment and correlation.
Mutual respect.
Corporate alignment.
Participative and shared leadership.
Continuing cooperation agreements and the forging of alliances.
The integration of research and health care.
Continuous improvement and perseverance.
Conceptual, methodological and technological innovation.
Sustainable management.
Procedural efficacy.
Efficiency in the optimisation of resources.
Transparency and public dissemination.
Continuous evaluation and accountability.
How the IJC creates, delivers and captures value

Improvement in patients’ quality of life

Scientific dissemination leads to confidence in relationships

Subsidies, private collaboration and patronage

Means: project office, innovation, human resources, financial, communication

Capture of competitive funding in Spain and internationally

Expenses structure

Partner network: hospitals, universities, scientific institutes, industry, organisations, local entities

Research activities
Our team
The highest governing body is the Board of Trustees, on which are represented: the Josep Carreras Foundation, the Catalan Government Ministry of Business and Knowledge, the Catalan Government Ministry of Health, the Autonomous University of Barcelona (UAB), the University of Barcelona (UB), Badalona Town Council, the Directorate General for Health Research and Planning, the Catalan Institute of Oncology, the Northern Metropolitan Territorial Area Administration, the Catalan Foundation for Research and Innovation, the Hospital Clinic/August Pi i Sunyer Institute for Biomedical Research (Idibaps), the UB Hospital Coordination Committee and the Research Centres of Catalonia Institution Foundation (iCERCA).

**Board of Trustees**

**President**

**Mr. Josep Carreras Coll**  
President of the Josep Carreras Leukaemia Research Institute

**First Vice-president**  
Catalan Government Minister of Business and Knowledge

**Second Vice-president**  
Catalan Government Minister of Health

**Members**  
Rector Autonomous University of Barcelona (UAB)  
Rector University of Barcelona (UB)  
Mayor of Badalona

**Director General for Research, Catalan Government Ministry of Business and Knowledge**

**Director General for Health Research and Planning**

**Deputy Director General for Health Research and Innovation**

**Director General Catalan Institute of Oncology**

**Administrator Northern Metropolitan Territorial Area**

**Secretary for Universities and Research, Catalan Government Ministry of Business and Knowledge**

**Director Catalan Foundation for Research and Innovation**

**Research Director Hospital Clinic - IDIBAPS**

**Treasurer of the Josep Carreras Leukaemia Foundation**

**Vice-president of the Josep Carreras Leukaemia Foundation**

**Trustee of the Josep Carreras Leukaemia Foundation**

**Administrator of the Josep Carreras Leukaemia Foundation**

**Vice-rector for Research and Transferability, Autonomous University of Barcelona (UAB)**

**University of Barcelona Hospital Coordination Committee**

**Secretary**

**Director of the Research Centres of Catalonia Institution Foundation (iCERCA)**
Delegate committee

President
Prof. Evarist Feliu,
Coordinator of the ICO-Germans Trias i Pujol Campus

Members
PRICS coordinator, Catalan Government Ministry of Health
Director General, Catalan Government Ministry of Health, Directorate General Health Resources Planning Regulation
Directorate General for Research, Catalan Government Ministry of Business and Knowledge
Director iCerca, CERCA Institution, Research Centres of Catalonia
Administrator, Josep Carreras International Foundation
University of Barcelona Commissioner for Hospital Coordination
Vice-rector for Strategic Projects and Planning, Autonomous University of Barcelona

CoExternal Scientific Committee

President
Prof. Lucio Luzzatto, Instituto Toscano Tumori Firenze

Members
Prof. Robert Sackstein, Dana-Farber/Harvard Cancer Center Boston
Prof. Francesco Lococo, Università degli Studi di Roma "Tor Vergata"
Prof. Alberto Orfao, CIC Centro de Investigación del Cáncer Salamanca
Prof. Brigitte Schlegelberger, University of Hannover

Internal Scientific Committee

UB-Clinik Campus
Álvaro Urbano Ispizúa (Internal Scientific Committee Coordinator)
Pablo Menéndez (Campus Research Director)
Jordi Esteve Reyner
Armando López Guillermo
Joan Bladé Creixent
Francisco Cervantes Requena

ICO-GTIP Campus
Evarist Feliu Frasnedo (President of the Delegate Committee)
Francesc Solé (Campus Research Director)
Josep Mª Ribera Santasusana
Lurdes Zamora Plana
José Tomás Navarro Ferrando
Juan Manuel Sancho Cía

Sant Pau Campus
Jordi Sierra
Josep Nomdedeu
Joan Carles Souto
Ramon Mangues
Carol Moreno
Organisational chart

Scientific directors

Campus ICO-GTP
Francesc Solé

Campus Clinic-UB
Pablo Menéndez

Campus Sant Pau
Jordi Sierra
Human resources

IJC Germans Trias

Linked with IJC
Aranda Cebrian, Jessica
Barque Falguera, Anna
Batista, Lopes
Buschbeck, Marcus
Cid Roldos, Emili
Corujo Garcia, David
Cousino de la Torre, Jorge
de Haro Camps, Nuria
Diesch, Jeannine
Douet Julien, Thierry
Estrada Barreras, Natalia
Fita Torro, Josep
Fuster Torno, Francisco
Garcia Calduch, Olga
Garcia Rico, Laura
Genesca Ferrer, Eulalia
Gomes Monteiro, Maria Joao
Gomez Marzo, Paula
Guberovic, Iva
Hurtado, Sarah
Ibarra Fernandez, Gladys
Llobet Reixach, Laura
Maher, Michael
Malinverni, Roberto
Mallo Fajula, Maria del Mar
Muncunill Farreyn, Josep
Palomo Sanchis, Laura
Pasquali, Lorenzo
Petriz Gonzalez, Jorge Mario
Ribera Salas, Jordi
Ruiz Cortes, Rocio
Sanchez Fernandez, M Carmen
Solanes Hernandez, Neus
Sole Ristol, Francesc
Valero Lazaro, Vanesa
Vavouri, Soutiana
Vidal Santorum, Adria
Yamamoto, Fumiichiro
Yamamoto, Miyako

IJC Clínico

Linked with IJC
Agraz Doblas, Antonio Manuel
Banus Mulet, Antonia
Bueno Uroz, Clara
Castaño Cardoso, Julio
Cobo Sanchez, Isabel
Diaz de la Guar Quiles, Rafael
Dominguez Mohedano, Sonia
Etxabe Alberdi, Amaia
Fernandez Martin, Adrian
Gutierrez Valle, Victoria
Krishnevskaya, Elena
Libero Baroni, Matteo
Llaudet Planas, Esther
Lopez Millan, Belen
Mañu Pereira, Maria del Mar
Masso Chacon, Anna
Menendez Bujan, Pablo
Mir Fuertes, Enrique
Molina Campoy, Oscar
Muñoz Riusueño, Ruth
Palomo de Udaeta, Marta
Prieto Fernandez, Cristina
Rizzutto, Valeria
Roca Ho, Heleia
Rodriguez Cortez, Virginia
Suñé Rodriguez, Guillermo
Torres Ruiz, Raul

IJC Sant Pau

Linked with IJC
Aljarilla Medina, Alba
Esquirol Sanfeliu, Albert
Millon Caño, Juan Antonio
Virgin Alamo Vargas, Patricia
IJC Germans Trias

Linked with hospital
Batle, Montse. Post doc
Cabezon, Marta. Post doc
Cisneros, Adela. Pre doc
Feliu, Evarist. Director
Ferra, Christelle. LR
Granada, Isabel. Post doc
Grau, Javier. Post doc
Junca, Jordi. Post doc
Marce, Silvia. Post doc
Milla, Fuensanta. Post doc
Navarro, Tomàs. LR
Oriol, Albert. LR
Ribera, Josep Maria. LR
Rodriguez, Inês. Pre doc
Ruiz, Neus. Pre doc
Sancho, Juanma. LR
Vives, Susana. Pre doc
Xandri, Marisol. Pre doc
Xicoy, Blanca. LR
Zamora, Lurdes. LR

IJC Clínica

Linked with hospital
Blade, Joan. LR
Esteve, Jordi. LR
Larrea, Carlos. Post doc
Urbano, Alvaro. Director

IJC Sant Pau

Linked with hospital
Barata, Ana. Post doc
Briones, Javier. LR
Mangues, Ramon. LR
Moreno, Carol. LR
Nomdedeu, Josep LR
Sierra, Jordi. Director
<table>
<thead>
<tr>
<th>Category</th>
<th>IJC ICO</th>
<th>IJC Clinic UB</th>
<th>IJC Sant Pau UAB</th>
<th>IJC Shared</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead researchers</td>
<td>7</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-doctoral researchers</td>
<td>9</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-doctoral researchers</td>
<td>6</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support staff</td>
<td>11</td>
<td>6</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Management and administration staff</td>
<td>1</td>
<td>6</td>
<td>3</td>
<td>24</td>
</tr>
</tbody>
</table>

**Staff professionally linked with the IJC**

<table>
<thead>
<tr>
<th>IJC ICO</th>
<th>IJC Clinic UB</th>
<th>IJC Sant Pau UAB</th>
<th>IJC Shared</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>22</td>
<td>3</td>
<td>24</td>
</tr>
</tbody>
</table>

**Staff professionally linked with the Hospital**

<table>
<thead>
<tr>
<th>IJC ICO</th>
<th>IJC Clinic UB</th>
<th>IJC Sant Pau UAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>15</td>
<td>19</td>
</tr>
</tbody>
</table>
At the three hospitals where the IJC has a presence there has always been a great willingness to participate in clinical research. And there are clinics with a very considerable background in basic sciences. Integration, in this respect, must therefore not be just a question of maintaining present levels, but of increasing them in order to enhance the added value it represents in both the health sciences and in clinical practice.
Financial data
In 2015 there was an increase of more than 180% in income from the capture of public funds and the provision of services.

With regard to expenses, 50% of the IJC's outlay corresponds to staffing, with an increase of almost 190% corresponding to the integration of new research teams (SUMA project). At this early stage the evolution of income, expenses and investments gives a negative result of €441,474.43.

<table>
<thead>
<tr>
<th>Income from activities</th>
<th>€3,378,582.43</th>
</tr>
</thead>
<tbody>
<tr>
<td>Services rendered</td>
<td>€530,190.71</td>
</tr>
<tr>
<td>Official subsidies for activities</td>
<td>€1,854,669.51</td>
</tr>
<tr>
<td>Other subsidies. donations…</td>
<td>€993,722.21</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Self-constructed assets</th>
<th>€33,567.19</th>
</tr>
</thead>
</table>

| Supplies                     | - €1,014,359.01 |

<table>
<thead>
<tr>
<th>Other income from activity</th>
<th>€10,402.02</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Staff costs</th>
<th>- €1,930,020.11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wages and salaries</td>
<td>- €1,495,891.70</td>
</tr>
<tr>
<td>Social security expenses</td>
<td>- €434,128.41</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other expenses</th>
<th>- €508,978.06</th>
</tr>
</thead>
<tbody>
<tr>
<td>External services</td>
<td>- €469,076.88</td>
</tr>
<tr>
<td>Taxes</td>
<td>- €359.20</td>
</tr>
<tr>
<td>Losses. depreciation…</td>
<td>- €33,567.19</td>
</tr>
<tr>
<td>Other current period losses</td>
<td>- €5,974.79</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fixed asset depreciation</th>
<th>- €441,474.43</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>IJC Subsidy</th>
<th>€47,270.14</th>
</tr>
</thead>
</table>

| Other income                 | €9.45         |

<table>
<thead>
<tr>
<th>OPERATING INCOME</th>
<th>- €425,000.38</th>
</tr>
</thead>
<tbody>
<tr>
<td>Financial income</td>
<td>€1,264.85</td>
</tr>
<tr>
<td>Financial expenses</td>
<td>- €15,155.43</td>
</tr>
</tbody>
</table>

| Subsidy return expenses     |               |

<table>
<thead>
<tr>
<th>Exchange rate differences</th>
<th>- €2,583.47</th>
</tr>
</thead>
</table>

| Financial result             | - €16,474.05  |

| Surplus / deficit before tax| - €441,474.43 |

| Tax on profit               |               |

| SURPLUS / DEFICIT OF THE FINANCIAL YEAR | - €441,474.43 |
Balance sheet

### ASSETS

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-current assets</strong></td>
<td>€10,682,445.23</td>
</tr>
<tr>
<td>Intangible fixed assets</td>
<td>€2,133,999.05</td>
</tr>
<tr>
<td>Tangible fixed assets</td>
<td>€8,515,466.90</td>
</tr>
<tr>
<td>Long-term investments in group and associated entities</td>
<td>€2,000.00</td>
</tr>
<tr>
<td>Long-term financial investments</td>
<td>€30,979.28</td>
</tr>
<tr>
<td><strong>Current assets</strong></td>
<td>€5,764,934.53</td>
</tr>
<tr>
<td>Stock</td>
<td>€3,200.00</td>
</tr>
<tr>
<td>Users, sponsors and other debtors from activities</td>
<td>€4,824,792.62</td>
</tr>
<tr>
<td>Other credits with the public administration</td>
<td></td>
</tr>
<tr>
<td>Short-term financial investments</td>
<td>€1,842.87</td>
</tr>
<tr>
<td>Short-term accruals</td>
<td>€40,413.37</td>
</tr>
<tr>
<td>Cash and others</td>
<td>€894,685.67</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>€16,447,379.76</td>
</tr>
</tbody>
</table>

### LIABILITIES

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net assets</strong></td>
<td>€8,235,607.91</td>
</tr>
<tr>
<td>Equity</td>
<td>€6,988,786.30</td>
</tr>
<tr>
<td>Start-up funds</td>
<td>€7,907,972.48</td>
</tr>
<tr>
<td>Special funds</td>
<td></td>
</tr>
<tr>
<td>Profit or loss from previous years</td>
<td>- €477,711.75</td>
</tr>
<tr>
<td>Year profit or loss</td>
<td>- €441,474.43</td>
</tr>
<tr>
<td>Subsidies, donations and legacies</td>
<td>€1,246,821.61</td>
</tr>
<tr>
<td><strong>Non-current liabilities</strong></td>
<td>€3,232,070.21</td>
</tr>
<tr>
<td>Long-term debt</td>
<td>€3,232,070.21</td>
</tr>
<tr>
<td><strong>Current liabilities</strong></td>
<td>€4,979,701.64</td>
</tr>
<tr>
<td>Short-term provisions</td>
<td>€41,567.19</td>
</tr>
<tr>
<td>Short-term debt</td>
<td>€2,917,787.95</td>
</tr>
<tr>
<td>Creditors for activities and others</td>
<td>€1,318,832.01</td>
</tr>
<tr>
<td>Short-term debts with group and associated entities</td>
<td></td>
</tr>
<tr>
<td>Current tax liabilities and other debts with the public administration</td>
<td></td>
</tr>
<tr>
<td>Short-term accruals</td>
<td>€701,514.49</td>
</tr>
<tr>
<td><strong>TOTAL (LIABILITIES + NA)</strong></td>
<td>€16,447,379.76</td>
</tr>
</tbody>
</table>
Evolution of income
Scientific activity
Research groups

IJC GermansTrias

Active projects: 18
LRs: 7

IJC Sant Pau

Thrombosis and Cancer
MM
Animal models: AML, DLBCL

IJC Clínic

Active projects: 18
LRs: 2

Stem Cells
ALL infant
AML
BMT
NHL
MM
MDS
## Research projects

<table>
<thead>
<tr>
<th>IP</th>
<th>Projects 2015</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>PABLO MENENDEZ</td>
<td>ERC</td>
<td>€2,000,000,00</td>
</tr>
<tr>
<td>ALVARO MUÑOZ</td>
<td>FPI MINECO</td>
<td>€88,400,00</td>
</tr>
<tr>
<td>F SOLE</td>
<td>FEDER</td>
<td>€336,698,60</td>
</tr>
<tr>
<td>F SOLE</td>
<td>PEJ MINECO</td>
<td>€35,800,00</td>
</tr>
<tr>
<td>SOULTANA VAVOURI</td>
<td>RyC MINECO</td>
<td>€26,623,00</td>
</tr>
<tr>
<td>DAVID CORUJO</td>
<td>FPU MECD</td>
<td>€64,534,00</td>
</tr>
<tr>
<td>MARCUS BUSCHBECK</td>
<td>RyC MINECO</td>
<td>€24,403,00</td>
</tr>
<tr>
<td>SOULTANA VAVOURI</td>
<td>BFU-30246</td>
<td>€39,980,00</td>
</tr>
<tr>
<td>Mª CARMEN SANCHEZ</td>
<td>SAF-40106</td>
<td>€54,175,00</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>€2,670,613,60</strong></td>
</tr>
</tbody>
</table>
### Capturing competitive grants

<table>
<thead>
<tr>
<th>Category</th>
<th>ICO Germans</th>
<th>Clinic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active projects (national)</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Projects awarded (national)</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Projects tendered (national)</td>
<td>37</td>
<td>17</td>
</tr>
<tr>
<td>Active projects (international)</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Projects awarded (international)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Projects tendered (international)</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Projects awarded (public)</td>
<td>17</td>
<td>2</td>
</tr>
<tr>
<td>Projects awarded (private)</td>
<td>16</td>
<td>8</td>
</tr>
<tr>
<td>Active research networks</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Research networks awarded</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Fundings

<table>
<thead>
<tr>
<th>Category</th>
<th>ICO Germans</th>
<th>Clinic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Competitive funding granted (€)</td>
<td>€603,359,00</td>
<td>€2,088,400,00</td>
</tr>
<tr>
<td>Non-competitive funding granted (€)</td>
<td>€675,305,00</td>
<td>€255,227,00</td>
</tr>
<tr>
<td>Sum total competitive and non-competitive overheads granted</td>
<td>€221,967,00</td>
<td>€455,964,00</td>
</tr>
</tbody>
</table>

![Graph showing competitive and non-competitive funding granted from 2012 to 2015](image)
Technology platforms

This year new equipment has arrived, such as the Fluidigm and a MFB Bioscience stereology system for the morphological study of lymphocyte populations.

Cytogenetics platform

The Josep Carreras Leukaemia Research Institute cytogenetics platform is directed by Dr. Francesc Solé. The platform includes the Catalan Institute of Oncology’s (ICO) Cytogenetics Laboratory and the 32K Bacterial Artificial Chromosome (BAK) library.

Affymetrix Microarrays Platform

The Affymetrix® Microarrays Platform (AMP) is a service focused on microarray DNA and RNA solutions provided by Affymetrix. The main aim is to find solutions, based on basic research, applied research and diagnosis, that lead towards personalised medicine.

Blood cancer samples

The administration of the collection, processing and storage of blood cancer samples. These samples are stored in a collection called ‘Collection of samples from patients with hematologic neoplasms’.

Fluidigm Platform

The Fluidigm platform is used to create integrated fluid circuits (IFCs) which are single-use biochips which automate PCR reactions using the volumes of nanolitres from two samples and reagents to produce consistent results.
Clinical trials

Clinical trials are a fundamental part of our research. In this regard, the IJC evaluates treatments, the efficacy of drugs, and the suitability of equipment.
It enables new treatments to be tested to prevent, relieve or cure diseases.

Transferability and innovation

The IJC vouches for the transferability of knowledge, and the value of and search for market opportunities, in the broadest terms. As well as being in its own interests, it contributes to society and our country's progress.

At the present time the IJC has the following patent pending:

**Methods for treating diagnosing and prognosing a haematological malignancy.**
Inventor: Ruth Muñoz Risueño
WO 2015/197839
PCT/EP2015/064571
Scientific production
Publications

Indexed articles

<table>
<thead>
<tr>
<th>Year</th>
<th>Articles</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>7</td>
</tr>
<tr>
<td>2012</td>
<td>16</td>
</tr>
<tr>
<td>2013</td>
<td>32</td>
</tr>
<tr>
<td>2014</td>
<td>55</td>
</tr>
<tr>
<td>2015</td>
<td>80</td>
</tr>
</tbody>
</table>

Publications 2016

- Total FI articles: 80
- Accumulated impact factor: 509.926
- Total citations: 1,221
- Citacion index: 39.976
Teaching activities
Teaching

The IJC provides a high-quality teaching programme for students, scientists, technicians and others with an interest in achieving a solid and up-to-date grounding in the field of leukaemia and malignant blood diseases.

The IJC organises a Doctorate in Hematology, a Master’s degree in malignant blood diseases and it participates in the teaching for degrees in medicine and biomedicine.

In 2015 the following theses were presented at the IJC:

**Molecular characterisation of tumour cells circulating in the peripheral blood of patients with breast cancer**
Doctoral student: Rosa Nadal Ríos (UAB)
Directors: Francesc Solé, Dr. Rafael Rosell and Dr. Mª José Serrano
Badalona, 23 January 2015

**Combination of cytogenetic techniques in chronic lymphocytic leukaemia**
Doctoral student: Anna Puiggros (UAB)
Directors: Francesc Solé, Blanca Espinet
Barcelona, 10 July 2015

**Bone density variations in hematopoietic progenitor transplants**
Doctoral student: S Holgado Perezl (UAB)
Directors: JM Ribera and A Olive
Badalona, 3 November 2015
The IJC organises complementary training activities at all levels, from scientific conferences, monthly seminars and technology sessions, to specialised courses.

Training courses
4

Scientific conference
1

Scientific seminars
12
Courses

Application of cytogenetics and FISH to the study of myelodysplastic syndromes. Celgene Internacional.
Badalona, 12 and 13 May 2015

Application of cytogenetics and FISH to the study of myelodysplastic syndromes. Celgene Internacional.
Badalona, 26 and 27 May 2015

Application of cytogenetics and FISH to the study of myelodysplastic syndromes. Celgene Internacional.
Badalona, 16 and 17 June 2015

CUBIMOL. Paper: Cytogenetic and genetic changes in myelodysplastic syndromes.
Speaker: Francesc Sole
Madrid 23-25 September 2015
Cooperation
Agreements

The IJC makes a great effort to establish continuing cooperation agreements, and it focuses on broadening its strategic alliances and agreements with the pharmaceutical industry, as well as other private organisations.

At the present time the following institutions are connected with the IJC:
Communication
The IJC knows that it is of prime importance to tell people about the work we do if we are to strengthen our bonds with society and its citizens. The desire to integrate social corporate responsibility into our management model is closely linked to the organisational values of the Josep Carreras Foundation.

To this end, the IJC has actively participated in scientific dissemination and in the creation of scientific vocations.
Upcoming challenges
Upcoming challenges

Construction of the new building in Badalona

In the summer of 2017 the IJC will take a big step forward in the field of research into leukaemia with the inauguration of the new building in Badalona.

The new building has 7,000m² of floor space, and it is the first European research centre to be exclusively focused on research into leukaemia and other malignant blood diseases.

Furthermore, it has been accredited as a sustainable building on account of its reduced environmental impact, savings in energy consumption, reduction in maintenance costs and the increased satisfaction and wellbeing of the people who use it.

SUMA agreement

The Government of the Generalitat de Catalunya has approved the project for the integration of the Institute for Predictive and Personalised Cancer Medicine (IMPPC) with the IGTP and the IJC, and there is a proposal for an agreement that the administrator of the IGTiP should also be the administrator of the IJC.

In this regard, work is taking place, together with the scientific management of the Germans Trias i Pujol Institute, with a view to sharing platforms and projects, and drafting a collaboration agreement which, once signed, can be applied to the other campuses.


41. **SORIGUÉ M, XICOY B, GRIFOLS JR, RIBERA JM.** [Autoimmune hemolytic anemia refractory to medical treatment after chlorine dioxide intake in a patient with idiopathic thrombocytopenic purpura]. *Med Clin (Barc)* 2015; 144(7):332-3. **IF. 1,252. Q3**


44. **ORIOL A.** Treatment of relapsed or refractory acute lymphoblastic leukemia in adult patients. *Acta Haematol* 2015;133(1):89-90. **IF. 0,994. Q4**


48


70. BERNAT GEL, ANNA DIEZ-VILLANUEVA, EDUARD SERRA, MARCUS BUSCHBECK, MIGUEL A. PEINADO AND ROBERTO MALINVERNI. regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests. Bioinformatics 2015 in press IF 4.981


72. VANESSA BARRAGAN, YOLANDA DIAZ, CRISTINA JUAN, JORDI RIBERA, JOSE TOMAS NAVARRO, FUENSANTA MILLÁ. Leucemia linfoblástica aguda (LLA B) en un adulto con doble cromosoma Philadelphia (Ph') y expresión de las isoformas p190 y p210. Revista: AETEL 15/09/2015, llibre 50, foli 13 i nº 102


77. GUILLEM BERBIS1, JORDI RIBERA1, JOSEP MARIA RIBERA1,2, EULÀLIA GENESCÀ. Implications of basic research in clinical practice: toward a personalized medicine in T-cell Acute Lymphoblastic Leukemia (T-ALL). Biological Science (Molecular Biology, OMICS group). Review. IF: 1.85. Accepted on 26.10.2015


Headquarters
C/ Muntaner, 383 3r. 08021
Barcelona
Tel. (+34) 93 414 55 66

For any matter concerning this report please contact:
comunicacio@carrerasresearch.org

The report can also be downloaded from:
http://www.carrerasresearch.org

Publisher, layout and typesetting
Josep Carreras Leukaemia Research Institute

Photography
Photographic archives of the Josep Carreras Leukaemia Foundation and the Josep Carreras Leukaemia Research Institute